Status:
COMPLETED
Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
To assess the maximum tolerated dose and overall safety and tolerability of sunitinib \[SU011248\] administered in combination with gefitinib (Iressa) for the treatment of patients with metastatic ren...
Eligibility Criteria
Inclusion
- Histologically confirmed renal cell carcinoma with metastases
- Evidence of unidimensionally measurable disease
- Failure of 1 prior immunotherapy or no prior systemic therapy for metastatic RCC
Exclusion
- RCC without any clear (conventional) cell component
- History of or known brain metastases
- Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study entry
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00113529
Start Date
October 1 2004
End Date
October 1 2008
Last Update
August 29 2011
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109
2
Pfizer Investigational Site
New York, New York, United States, 10021
3
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States, 19111-2497